- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Gillian Woollett, MA, DPhil: Policy and Biosimilars
Gillian Woollett, MA, DPhil, senior vice president of Avalere, discusses policy and biosimilars in the United States.
Transcript:
Are there policy changes that would make the United States a better market for biosimilars?
Definitely we need policy changes, but how quickly we can implement what needs legislation, what needs regulations…all of those are delays, so I think what it comes down to is people understanding better what biosimilars offer; that as an economic matter they are essentially generics, and realizing because they’re approved by the FDA they are of the same quality and will have the same clinical outcomes as their reference. There are questions being raised that make it very, very difficult for biosimilars to penetrate. Plus, it takes a significant investment—about $500 million, a hundred times a generic—to get them to market. So, there needs to be a return on investment and yet, they’re being treated like brands, expected to be cheaper but costing more to produce. And so it’s a serious uphill battle.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
British Columbia’s Biosimilar Policy Shows No Impact on Hospital Visits
May 28th 2025Despite a dramatic shift toward biosimilar use following British Columbia’s policy, researchers found no rise in hospital visits or complications, underscoring the real-world reliability of etanercept biosimilars in managing inflammatory arthritis.
